Izaak Walton Killam Health Centre

Running trials

• Recruiting

  Pilot Study of IT Topotecan and Maintenance Chemotherapy for HR-EBTs in Children < 6 Years, Post Consolidation

  NCT06942039· Early phase 1· C17 Council· Source

• Recruiting

  CANnabinoids in Pediatric ONCology

  NCT05754840· Phase 1/2· University of Manitoba· Source

• Recruiting

  A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)

  NCT06124157· Phase 2· National Cancer Institute (NCI)· Source

• Recruiting

  A Study Using Risk Factors to Determine Treatment for Children With Favorable Histology Wilms Tumors (FHWT)

  NCT06401330· Phase 3· Children's Oncology Group· Source

• Recruiting

  Testing a Standardized Approach to Surgery and Chemotherapy for Type I Pleuropulmonary Blastoma or the Addition of an Anti-cancer Drug, Topotecan, to the Usual Treatment for Types II and III Pleuropulmonary Blastoma

  NCT06647953· Phase 3· Children's Oncology Group· Source

• Recruiting

  A Study of Lower Radiotherapy Dose to Treat Children With CNS Germinoma

  NCT06368817· Phase 2· Children's Oncology Group· Source

• Recruiting

  Sertraline vs. Placebo in the Treatment of Anxiety in Children and AdoLescents With NeurodevelopMental Disorders

  NCT06081348· Phase 2· Holland Bloorview Kids Rehabilitation Hospital· Source

• Active, not recruiting

  Crohn's Disease: Efficacy, Safety, and Pharmacokinetics of Upadacitinib in Pediatric Subjects With Moderately to Severely Active Crohn's Disease

  NCT06332534· Phase 3· AbbVie· Source

• Recruiting

  Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma

  NCT06172296· Phase 3· National Cancer Institute (NCI)· Source

• Recruiting

  CfDNA in Hereditary And High-risk Malignancies 2

  NCT06726642· University Health Network, Toronto· Source

• Recruiting

  A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease

  NCT05509777· Phase 3· Eli Lilly and Company· Source

• Recruiting

  A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease

  NCT05923073· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  Reverse-Engineering of Exclusive Enteral Nutrition (RE-EEN) in Crohn's Disease: A Multi-Center Trial

  NCT06216899· Seattle Children's Hospital· Source

• Active, not recruiting

  A Study of Revumenib in Combination With Chemotherapy for Patients Diagnosed With Relapsed or Refractory Leukemia

  NCT05761171· Phase 2· Children's Oncology Group· Source

• Recruiting

  Cord Clamping Among Neonates With Congenital Heart Disease

  NCT06153459· Carl Backes, MD· Source

• Active, not recruiting

  Study to Assess Adverse Events, Change in Disease Activity, and How Oral Upadacitinib Moves Through the Body of Pediatric Participants With Moderately to Severely Active Ulcerative Colitis.

  NCT05782907· Phase 3· AbbVie· Source

• Active, not recruiting

  Studying the Effect of Levocarnitine in Protecting the Liver From Chemotherapy for Leukemia or Lymphoma

  NCT05602194· Phase 3· Children's Oncology Group· Source

• Recruiting

  A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab

  NCT05675410· Phase 3· National Cancer Institute (NCI)· Source

• Recruiting

  A Study of Treatment for Medulloblastoma Using Sodium Thiosulfate to Reduce Hearing Loss

  NCT05382338· Phase 3· Children's Oncology Group· Source

• Active, not recruiting

  Firefighters Preventing Cancer Online Training Program

  NCT05745246· IWK Health Centre· Source

• Active, not recruiting

  Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)

  NCT05183035· Phase 3· PedAL BCU, LLC· Source

• Recruiting

  Chemotherapy for the Treatment of Patients With Newly Diagnosed Very Low-Risk and Low Risk Fusion Negative Rhabdomyosarcoma

  NCT05304585· Phase 3· Children's Oncology Group· Source

• Recruiting

  Effect of Metformin on Behaviour and the Brain in Children Treated for a Brain Tumour

  NCT05230758· Phase 3· Donald Mabbott· Source

• Active, not recruiting

  A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG)

  NCT05099003· Phase 1/2· National Cancer Institute (NCI)· Source

• Recruiting

  The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study

  NCT04726241· Phase 1/2· PedAL BCU, LLC· Source

• Recruiting

  Thoracotomy Versus Thoracoscopic Management of Pulmonary Metastases in Patients With Osteosarcoma

  NCT05235165· Phase 3· Children's Oncology Group· Source

• Active, not recruiting

  Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma

  NCT04759586· Phase 3· National Cancer Institute (NCI)· Source

• Active, not recruiting

  A Study to Compare Early Use of Vinorelbine and Maintenance Therapy for Patients With High Risk Rhabdomyosarcoma

  NCT04994132· Phase 3· Children's Oncology Group· Source

• Active, not recruiting

  Evaluation of Oral Tofacitinib in Children Aged 2 to 17 Years Old Suffering From Moderate to Severe Ulcerative Colitis

  NCT04624230· Phase 3· Pfizer· Source

• Recruiting

  A Study of a New Way to Treat Children and Young Adults With a Brain Tumor Called NGGCT

  NCT04684368· Phase 2· Children's Oncology Group· Source

• Recruiting

  Hypertrophic Cardiomyopathy Registry, Biobank and Imaging Data Repository

  NCT05100420· Montreal Heart Institute· Source

• Active, not recruiting

  Treatment With Dinutuximab, Sargramostim (GM-CSF), and Isotretinoin in Combination With Irinotecan and Temozolomide After Intensive Therapy for People With High-Risk Neuroblastoma (NBL)

  NCT04385277· Phase 2· Children's Oncology Group· Source

• Recruiting

  A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)

  NCT04546399· Phase 2· National Cancer Institute (NCI)· Source

• Active, not recruiting

  Mobile Health and Social Media Physical Activity Intervention Among Adolescent and Young Adult Childhood Cancer Survivors, the StepByStep Study

  NCT04089358· Phase 3· Children's Oncology Group· Source

• Recruiting

  A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWT

  NCT04322318· Phase 2· Children's Oncology Group· Source

• Recruiting

  A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

  NCT04293562· Phase 3· Children's Oncology Group· Source

• Active, not recruiting

  A Study of the Drugs Selumetinib Versus Carboplatin/Vincristine in Patients With Neurofibromatosis and Low-Grade Glioma

  NCT03871257· Phase 3· National Cancer Institute (NCI)· Source

• Active, not recruiting

  Stopping Tyrosine Kinase Inhibitors in Affecting Treatment-Free Remission in Patients With Chronic Phase Chronic Myeloid Leukemia

  NCT03817398· Phase 2· Children's Oncology Group· Source

• Recruiting

  Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

  NCT03959085· Phase 3· Children's Oncology Group· Source

• Active, not recruiting

  Larotrectinib in Treating Patients With Previously Untreated TRK Fusion Solid Tumors and TRK Fusion Relapsed Acute Leukemia

  NCT03834961· Phase 2· Children's Oncology Group· Source

• Active, not recruiting

  Irinotecan Hydrochloride, Temozolomide, and Dinutuximab With or Without Eflornithine in Treating Patients With Relapsed or Refractory Neuroblastoma

  NCT03794349· Phase 2· Children's Oncology Group· Source

• Active, not recruiting

  A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia

  NCT03914625· Phase 3· National Cancer Institute (NCI)· Source

• Active, not recruiting

  Veliparib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Malignant Glioma Without H3 K27M or BRAFV600 Mutations

  NCT03581292· Phase 2· Children's Oncology Group· Source

• Active, not recruiting

  Trametinib for Pediatric Neuro-oncology Patients With Refractory Tumor and Activation of the MAPK/ERK Pathway.

  NCT03363217· Phase 2· St. Justine's Hospital· Source

• Active, not recruiting

  Cell-free DNA in Hereditary And High-Risk Malignancies 1

  NCT04261972· University Health Network, Toronto· Source

• Active, not recruiting

  Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery

  NCT03533582· Phase 3· Children's Oncology Group· Source

• Recruiting

  Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)

  NCT03126916· Phase 3· Children's Oncology Group· Source

• Active, not recruiting

  A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn's Disease

  NCT03105102· Phase 3· AbbVie· Source

• Active, not recruiting

  Reduced Craniospinal Radiation Therapy and Chemotherapy in Treating Younger Patients With Newly Diagnosed WNT-Driven Medulloblastoma

  NCT02724579· Phase 2· Children's Oncology Group· Source

• Active, not recruiting

  Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

  NCT03007147· Phase 3· Children's Oncology Group· Source

Showing 50 of 66.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Childhood cancers22 recruiting
• Acute lymphoblastic leukaemia4 recruiting
• Crohn's disease3 recruiting
• Down syndrome3 recruiting
• Neuroblastoma3 recruiting
• Acute myeloid leukaemia2 recruiting
• Kidney cancer2 recruiting
• Ovarian cancer2 recruiting
• Sarcoma2 recruiting
• Congenital heart disease1 recruiting
• Gastric and oesophageal cancer1 recruiting
• Hearing loss1 recruiting
• Hypertrophic cardiomyopathy1 recruiting
• Lung cancer1 recruiting
• Myelodysplastic syndromes1 recruiting
• Myeloproliferative neoplasms1 recruiting
• Neuroendocrine tumours1 recruiting
• Psoriasis1 recruiting
• Psoriatic arthritis1 recruiting
• Rheumatoid arthritis1 recruiting

Closed trials

• Completed

  The Effect of In-utero Exposure to Metformin in 5-11 Year Old Offspring of Mothers in the MiTy Trial

  NCT05025852· Mount Sinai Hospital, Canada· Source

• Completed

  High-exchange ULTrafiltration to Enhance Recovery After Pediatric Cardiac Surgery

  NCT04920643· IWK Health Centre· Source

• Terminated

  Personalized AZithromycin/metronidAZole Therapy in Pediatric Crohn's Disease (CD)

  NCT04186247· Phase 2· University of North Carolina, Chapel Hill· Source

• Completed

  Closed-loop Insulin Delivery In Type 1 Diabetes Pregnancies (CIRCUIT)

  NCT04902378· University of Calgary· Source

• Completed

  HRQL and Symptom Assessment for Patients With DIPG or Recurrent and Re-irradiated Brain Tumours and Their Caregivers

  NCT04670016· University of Calgary· Source

• Completed

  Pain Burden in Children and Adolescents With Cerebral Palsy

  NCT04219020· Sykehuset Telemark· Source

• Completed

  The Pain Squad+ Smartphone App To Support Real-Time Pain Management for Adolescents With Cancer

  NCT03632343· The Hospital for Sick Children· Source

• Completed

  Biospecimen Analysis in Determining Effects of Chemotherapy on Fertility in Osteosarcoma Survivors

  NCT03206450· Children's Oncology Group· Source

• Completed

  Re-Irradiation of Progressive or Recurrent DIPG

  NCT03126266· University of Calgary· Source

• Completed

  Azacitidine and Combination Chemotherapy in Treating Infants With Acute Lymphoblastic Leukemia and KMT2A Gene Rearrangement

  NCT02828358· Phase 2· National Cancer Institute (NCI)· Source

• Completed

  Carvedilol in Preventing Heart Failure in Childhood Cancer Survivors

  NCT02717507· Phase 2· Children's Oncology Group· Source

• Completed

  Denosumab in Treating Patients With Recurrent or Refractory Osteosarcoma

  NCT02470091· Phase 2· Children's Oncology Group· Source

• Completed

  Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery

  NCT02180867· Phase 2/3· National Cancer Institute (NCI)· Source

• Completed

  Blood Sample Markers of Reproductive Hormones in Assessing Ovarian Reserve in Younger Patients With Newly Diagnosed Lymphomas

  NCT01793233· Children's Oncology Group· Source

• Completed

  Busulfan, Melphalan, and Stem Cell Transplant After Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma

  NCT01798004· Phase 1· Children's Oncology Group· Source

• Completed

  Low-Dose or High-Dose Lenalidomide in Treating Younger Patients With Recurrent, Refractory, or Progressive Pilocytic Astrocytoma or Optic Pathway Glioma

  NCT01553149· Phase 2· National Cancer Institute (NCI)· Source

• Completed

  Chemotherapy Followed by Radiation Therapy in Treating Younger Patients With Newly Diagnosed Localized Central Nervous System Germ Cell Tumors

  NCT01602666· Phase 2· Children's Oncology Group· Source

• Completed

  Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations

  NCT02883049· Phase 3· National Cancer Institute (NCI)· Source

• Completed

  Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

  NCT01371981· Phase 3· National Cancer Institute (NCI)· Source

• Completed

  Vorinostat, Temozolomide, or Bevacizumab in Combination With Radiation Therapy Followed by Bevacizumab and Temozolomide in Young Patients With Newly Diagnosed High-Grade Glioma

  NCT01236560· Phase 2/3· National Cancer Institute (NCI)· Source

• Completed

  Combination Chemotherapy in Treating Patients With Non-Metastatic Extracranial Ewing Sarcoma

  NCT01231906· Phase 3· Children's Oncology Group· Source

• Completed

  Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma

  NCT01190930· Phase 3· Children's Oncology Group· Source

• Completed

  Maintenance Chemotherapy or Observation Following Induction Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Ependymoma

  NCT01096368· Phase 3· Children's Oncology Group· Source

• Completed

  Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer

  NCT00980460· Phase 3· National Cancer Institute (NCI)· Source

• Completed

  Combination Chemotherapy and Surgery in Treating Young Patients With Wilms Tumor

  NCT00945009· Phase 3· Children's Oncology Group· Source

• Completed

  A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia (CML) or With Ph+ Leukemias Resistant or Intolerant to Imatinib

  NCT00777036· Phase 2· Bristol-Myers Squibb· Source

• Completed

  Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

  NCT00557193· Phase 3· Children's Oncology Group· Source

• Completed

  Combination Chemotherapy Followed By Peripheral Stem Cell Transplant in Treating Young Patients With Newly Diagnosed Supratentorial Primitive Neuroectodermal Tumors or High-Risk Medulloblastoma

  NCT00336024· Phase 3· Children's Oncology Group· Source

• Completed

  Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed, Previously Untreated, High-Risk Medulloblastoma/PNET

  NCT00392327· Phase 3· Children's Oncology Group· Source

• Completed

  Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Newly Diagnosed Stage III or Stage IV Wilms' Tumor

  NCT00379340· Phase 3· Children's Oncology Group· Source

• Completed

  Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma

  NCT00408005· Phase 3· National Cancer Institute (NCI)· Source

• Completed

  Vincristine, Dactinomycin, and Doxorubicin With or Without Radiation Therapy or Observation Only in Treating Younger Patients Who Are Undergoing Surgery for Newly Diagnosed Stage I, Stage II, or Stage III Wilms' Tumor

  NCT00352534· Phase 3· Children's Oncology Group· Source

• Completed

  Treating Young Patients With Newly Diagnosed, Low Stage, Lymphocyte Predominant Hodgkin Disease

  NCT00107198· Phase 2· Children's Oncology Group· Source

• Completed

  Study of Kidney Tumors in Younger Patients

  NCT00898365· Children's Oncology Group· Source

• Completed

  Comparison of Radiation Therapy Regimens in Combination With Chemotherapy in Treating Young Patients With Newly Diagnosed Standard-Risk Medulloblastoma

  NCT00085735· Phase 3· Children's Oncology Group· Source

• Completed

  Genetic Analysis in Identifying Late-Occurring Complications in Childhood Cancer Survivors

  NCT00082745· Children's Oncology Group· Source

• Completed

  Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma

  NCT00026312· Phase 3· National Cancer Institute (NCI)· Source

• Completed

  Biomarkers in Tumor Tissue Samples From Patients With Newly Diagnosed Neuroblastoma or Ganglioneuroblastoma

  NCT00904241· Children's Oncology Group· Source

Conditions

Diseases this institution publishes on or runs trials for.

• Lyme disease3 works · 0 trials